New Path is delighted to announce that it has won grant funding from Innovate UK Cancer Therapeutics (Biomedical Catalyst) to further develop it’s novel PS targeting tumour agnostic drug conjugates for hard-to-treat cancers including colon and pancreas. Colon cancer and pancreatic cancer affect more than 1.4 million people every year and have a very poor prognosis, particularly when diagnosis is late. The grant will be used to optimise New Path’s molecules to improve efficacy in-vivo.
Innovate UK, part of UK Research and Innovation (UKRI), is the UK’s innovation agency. It works to create a better future by inspiring, involving and investing in businesses developing life-changing innovations. Its mission is to help companies to grow through their development and commercialisation of new products, processes and services, supported by an outstanding innovation ecosystem that is agile, inclusive and easy to navigate.
Innovate UK: inspiring business innovation.